NEW YORK – Cancer diagnostics firm Imagene on Wednesday announced that it is collaborating with Tempus AI to launch an AI-based biomarker prediction panel for non-small cell lung cancer.
Imagene's AI-based multigene panel for predicting non-small cell lung cancer biomarkers directly from biopsy images will be combined with Tempus' real-world data to continuously refine Imagene's lung AI models, Imagene said in a statement. The biomarkers may include EGFR, ALK, MET, BRAF, HER2, RET, and ROS1.
The bundled diagnostic offering will include molecular testing and an AI panel.
"By bringing together Imagene's AI expertise and Tempus' clinical reach, we are not only enhancing and democratizing access to precision diagnostics but also setting a new benchmark for lung cancer care — with the aim of delivering more personalized treatment options for physicians and their patients," Imagene CEO and Cofounder Dean Bitan said in a statement.